INOVIO Announces Pricing of $20.0 Million Public Offering
PR Newswire
PLYMOUTH MEETING, Pa., July 29, 2026
PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 21,052,632 shares of its common stock and accompanying warrants to purchase up to 42,105,264 shares of its common stock (or pre-funded warrants in lieu thereof) with an exercise price of $1.10 per share of common stock, at a combined public offering price of $0.95 per share of common stock and accompanying warrant to purchase two shares of common stock. INOVIO also granted the underwriter an option for a period of 30 days to purchase up to 3,157,894 additional shares of the Company's common stock and/or warrants to purchase up to 6,315,788 additional shares of its common stock (or pre-funded warrants in lieu thereof) at the public offering price, less the underwriting discounts and commissions. All of the securities in the offering are being sold by INOVIO. The offering is expected to close on or about July 31, 2026, subject to the satisfaction of customary closing conditions.
